Razi Ingber
CIK: 0002113213
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RDHL
RedHill Biopharma Ltd.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Ingber Razi
Ingber Razi (SEC CIK 0002113213) files insider reports with the SEC as Chief Financial Officer of RedHill Biopharma Ltd. (RDHL).
Signal8 holds 1 ownership filing by Ingber Razi, a Form 3, filed on Mar 18, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Ingber Razi's filings is in TEL AVIV.
Other insiders filing for RedHill Biopharma Ltd. (RDHL)
- Raday Gilead, Chief Operating Officer
- Tsimchi Ofer, Director
- Scruggs Rick D, Chief Commercial Officer
- Reed Kenneth, Director
- Mamluk Roni, Director
- Goldberg Guy Joel, Chief Business Officer